CD271 is a functional and targetable marker of tumor-initiating cells in head and neck squamous cell carcinoma

Murillo, Oihana; Chung, Man Ki; Shin, June Ho; Karamboulas, Christina; Kwok, Shirley; Jung, Young Ho; Oakley, Richard; Tysome, James R.; Farnebo, Lovisa; Kaplan, Michael; Sirjani, Davud; Divi, Vasu; Holsinger, F. Christopher; Tomeh, Chafeek; Nichols, Anthony C.; Le, Quynh Thu; Colevas, A. A. Dimitrios; Kong, Christina S.; Uppaluri, Ravindra; Lewis, James S.; Ailles, Laurie; Sunwoo, John B.

doi:10.18632/oncotarget.2269

Cited by 66 publications

(71 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1B) (Zhou et al 2007;Clay et al 2010). Recently, additional potential CSC surface markers have been identified, including CD10 (Fukusumi et al 2014), CD98 (Martens-de Kemp et al 2013), CD271 (Murillo-Sauca et al 2014), CD166 (Yan et al 2013), and ABCG2 (Wan et al 2010;Table). A separate method of isolation and identification of CSCs has been through the increased ability of CSCs to efflux Hoechst 33342 dye (due to increased activity of CSC membrane transporters).…”

Section: Cell Markersmentioning

confidence: 99%

“…A study conjugating a bacterial toxin (cytolethal distending toxin) to an anti-human CD133 monoclonal antibody demonstrated inhibition of cell proliferation (Damek-Poprawa et al 2011), whereas another study using a single-chain variable fragment targeting CD133 showed marked reduction in tumor proliferation in cell and mouse models (Waldron et al 2011). Inhibition of CD271, as well, has been demonstrated in cell models to decrease tumor formation (Murillo-Sauca et al 2014). Overall, targeting CSC surface markers remains an intriguing option for treatment.…”

Section: Targeting Cell Surface Markersmentioning

confidence: 99%

See 1 more Smart Citation

Targeting Head and Neck Cancer Stem Cells

2015

View full text Add to dashboard Cite

Cancer stem cells (CSCs), or tumor-initiating cells, comprise a subset of tumor cells with demonstrated ability for tumor growth, invasion, metastasis, and resistance to chemotherapy and radiation. Targeting of CSCs remains an attractive yet elusive therapeutic option, with the goal of increasing specificity and effectiveness in tumor eradication, as well as decreasing off-target or systemic toxicity. Research into further characterization and targeted therapy toward head and neck CSCs is an active and rapidly evolving field. This review discusses the current state of research into therapy against head and neck CSCs and future directions for targeted therapy.

show abstract

Section: Cell Markersmentioning

confidence: 99%

Section: Targeting Cell Surface Markersmentioning

confidence: 99%

Targeting Head and Neck Cancer Stem Cells

2015

View full text Add to dashboard Cite

show abstract

“…The FACS analysis has assessed not only the mesenchymal origin but also the non-malignancy of our clone. In particular, the negative results obtained analyzing the main surface markers expressed within the majority of solid tumors (CD133, CD117, CD34 and CD271) (23)(24)(25)(26)(27), together with the cell inability to form colonies in soft agar (28), confirmed that no malignant transformation occurred during cloning of PDL cells. In order to assess its potential and capability to differentiate into different lineages, we induced the clonal CD44+ PDL line toward adipogenic and osteogenic phenotypes.…”

Section: Discussionmentioning

confidence: 91%

The effect of strontium chloride on human periodontal ligament stem cells

Romagnoli

Zonefrati

Galli

et al. 2017

ccmbm

View full text Add to dashboard Cite

SummaryThe complete repair of periodontal structures remains an exciting challenge that prompts researchers to develop new treatments to restore the periodontium. Recent research has suggested strontium ion to be an attractive candidate to improve osteogenic activity. In this study, we have isolated a clonal finite cell line derived from human periodontal ligament (PDL) in order to assess whether and in which way different doses of SrCl2 (from 0.5 to 500 μg/ml) can influence both the proliferation and the mineralization process, for future application in oral diseases. PDL cells were cloned by dilution plating technique and characterized by FACS. Cell proliferation analysis and mineralization were performed by [ 3 H]-thymidine incorporation and spectrofluorometric assay. Results have evidenced that the higher SrCl2 concentrations tested, from 25 to 500 μg/ml, have increased the proliferation activity after only 24 h of treatment. Interestingly, the same higher concentrations have decreased the mineralization, which was conversely increased by the lower ones, from 0.5 to 10 μg/ml. Our findings suggest the possible use of SrCl2 in appropriate delivery systems that release, at different time points, the specific dose, depending on the biological response that we want to induce on periodontal ligament stem cells, providing a more efficient periodontal regeneration.

show abstract

“…CD271 + MSCs demonstrated also higher cell proliferation capacity compared to the entire PA-MSC population [23]. However, CD271 has been also identified as a marker of tumor initiating cells that may affect cell survival and proliferation [24][25][26].…”

Section: Cd271 Mscs In Ivd Regenerationmentioning

confidence: 99%

The feasibility of the CD271+ and CD271– mesenchymal stromal cell enrichment toward nucleus pulposus-like cells

Jezierska-Woźniak

Barczewska

Habich

et al. 2017

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

introduction. Factors promoting nerve cell ingrowth are considered responsible for chronic back pain resulting from the intervertebral disc degeneration (IDD). One of the recent exploratory IDD treatments is stem cell transplantation therapy. The CD271 (low-affinity nerve growth factor receptor) has been identified as a marker of the most homogeneous mesenchymal stem cell (MSC) subset. It is capable of promoting differentiation along adipogenic, osteogenic and chondrogenic lineages and producing significantly higher levels of cytokines as compared to the total population of plastic adherence-mesenchymal stem cells (PA-MSCs). We investigated the ability of CD271 + MSCs to differentiate into chondrocyte-like cells of the nucleus pulposus (NP) of intervertebral disc. We also examined CD271 -MSCs, using PA-MSCs as a control cell population. Material and methods. Bone marrow derived PA-MSCs and its two subsets, CD271 -MSCs and CD271 + MSCs, were seeded in collagen scaffolds. After two weeks of growth in NP-differentiation medium, RNA was isolated from cells-scaffold constructs and was analyzed by q-PCR for expression of NP markers. Glycosaminoglycans were analyzed biochemically directly in cells-scaffold constructs. results. Expression of NP markers -extracellular matrix components such as aggrecan, collagen type II and glycosaminoglycans on both RNA and the protein levels -was significantly higher in CD271-MSCs compared to the CD271 + MSCs and PA-MSCs cell populations. Conclusions. CD271-MSCs may be superior candidates for NP restorative treatment compared to CD271 + MSCs and PA-MSCs due to their ability of expressing NP-supporting extracellular matrix components at levels higher than the other two studied MSC subsets.

show abstract

CD271 is a functional and targetable marker of tumor-initiating cells in head and neck squamous cell carcinoma

Cited by 66 publications

References 39 publications

Targeting Head and Neck Cancer Stem Cells

Targeting Head and Neck Cancer Stem Cells

The effect of strontium chloride on human periodontal ligament stem cells

The feasibility of the CD271+ and CD271– mesenchymal stromal cell enrichment toward nucleus pulposus-like cells

Contact Info

Product

Resources

About